AOD-9604

Aperçu du produit

AOD-9604 (Anti-Obesity Drug 9604) is a modified C-terminal fragment of human growth hormone consisting of amino acids 176–191, with a tyrosine substitution at the N-terminal end. Unlike full-length HGH, AOD-9604 focuses exclusively on fat metabolism without triggering unwanted hormonal effects such as hyperglycemia or reduced insulin secretion. Originally developed as an anti-obesity compound, AOD-9604 stimulates lipolysis — the breakdown of stored fat for energy — while reducing lipogenesis, the formation of new fat. Research also shows it retains bone-stimulating properties of HGH through direct action on osteoblasts.

Mécanisme d'action

AOD-9604 retains the lipolytic activity of the HGH C-terminal domain while lacking the growth-promoting effects of the full hormone. It increases plasma glycerol levels (a key lipolysis marker) and enhances whole-body fat oxidation. These effects are partly mediated through interactions with the beta-adrenergic pathway, particularly by influencing beta(3)-adrenergic receptor expression in adipose tissue.

Principaux avantages

Amélioration du métabolisme — AOD-9604 increases basal metabolic rate by stimulating fat oxidation. Unlike HGH, it achieves these effects without inducing hyperglycemia or reducing insulin secretion. Users report more sustained energy throughout the day and increased daily activity levels.

Fat Reduction & Weight Management — By mobilizing stored fat cells and accelerating lipolysis, AOD-9604 supports weight loss while minimizing lean muscle loss. Its dual action on fat breakdown and appetite reduction makes it effective for improving body composition.

Anti-Aging Support — Emerging research highlights AOD-9604's potential to counteract age-related metabolic slowdown. Users report improvements in skin elasticity, overall radiance, and reduced visible signs of aging linked to improved metabolic function at the cellular level.

Références

1. Ng FM, Sun J, Sharma L, et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. *Horm Res.* 2000;53(6):274–278.
2. Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. *Clin Pharmacol Ther.* 2010;87(6):652–662.
3. Rodriguez-Arnao J, et al. Effects of growth hormone replacement on physical performance and body composition in GH deficient adults. *Clin Endocrinol.* 1999;51(1):53–60.